Artelo Biosciences, Inc. (ARTL) Income Statement
ARTL 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsARTL revenue and net income
ARTL growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ARTL quarterly EPS vs estimates
Artelo Biosciences beat the analyst EPS estimate in 2 of the last 6 quarters. Next report: November 11, 2026.
ARTL income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Research & development | $5.4M | $6.0M | $5.7M | $4.3M | $2.8M | $1.9M | $1.1M | $1.2M | $1.2M | $1.2M |
| Sales, general & admin | $6.0M | $4.1M | $4.2M | $6.0M | $4.6M | $2.8M | $2.1M | $1.1M | $232,789 | $29,690 |
| Total operating expenses | $11.4M | $10.1M | $9.9M | $10.3M | $7.4M | $4.7M | $3.2M | $2.3M | $232,789 | $29,690 |
| Operating income | −$11.4M | −$10.1M | −$9.9M | −$10.3M | −$7.4M | −$4.7M | −$3.2M | −$2.3M | −$232,789 | −$29,690 |
| Interest income | — | — | $0 | $1,000 | $2,000 | $1,000 | $1.0M | — | — | — |
| Interest expense | $194,000 | $0 | $0 | $5,000 | $0 | $0 | $0 | $0 | $2,100 | $0 |
| Income before taxes | −$12.9M | −$9.8M | −$9.3M | −$10.1M | −$7.4M | −$4.7M | −$2.2M | −$2.3M | −$234,889 | −$29,690 |
| Income taxes | — | — | — | −$209,000 | −$4,000 | −$60,414 | −$2.0M | $8 | $0 | $0 |
| Net income | −$12.9M | −$9.8M | −$9.3M | −$10.1M | −$7.4M | −$4.7M | −$2.2M | −$2.3M | −$234,889 | −$29,690 |
| EBITDA | −$12.5M | −$9.8M | −$9.3M | −$10.1M | −$7.4M | −$4.7M | −$4.2M | −$2.3M | −$232,789 | −$29,690 |
| EPS (diluted) | −$41.82 | −$21.75 | −$56.52 | −$32.38 | −$76.80 | −$221.70 | −$132.95 | −$0.30 | −$474.74 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $876,000 | $773,000 | $893,000 | $1.3M | $1.9M | $1.4M | $2.5M | $325,000 | $1.7M | $1.5M | $2.1M | $1.6M |
| Sales, general & admin | $1.6M | $1.9M | $1.9M | $1.8M | $1.3M | $995,000 | $1.3M | $870,000 | $827,000 | $1.1M | $1.1M | $1.0M |
| Total operating expenses | $2.5M | $2.7M | $2.8M | $3.1M | $3.1M | $2.4M | $3.8M | $1.2M | $2.5M | $2.6M | $3.2M | $2.6M |
| Operating income | −$2.5M | −$2.7M | −$2.8M | −$3.1M | −$3.1M | −$2.4M | −$3.8M | −$1.2M | −$2.5M | −$2.6M | −$3.2M | −$2.6M |
| Interest income | $42,000 | $1,000 | — | $5,000 | $1,000 | $7,000 | — | $0 | $0 | $0 | $0 | $0 |
| Interest expense | $6,000 | $124,000 | $377,000 | $111,000 | $72,000 | $0 | — | $0 | $0 | — | $0 | $0 |
| Income before taxes | −$2.4M | −$3.0M | −$4.2M | −$3.1M | −$3.2M | −$2.4M | −$3.8M | −$1.1M | −$2.4M | −$2.5M | −$3.1M | −$2.4M |
| Income taxes | — | — | — | — | — | — | — | — | — | — | — | $165,000 |
| Net income | −$2.4M | −$3.0M | −$4.2M | −$3.1M | −$3.2M | −$2.4M | −$3.8M | −$1.1M | −$2.4M | −$2.5M | −$3.1M | −$2.4M |
| EBITDA | −$2.4M | −$2.8M | −$3.8M | −$3.0M | −$3.1M | −$2.4M | −$3.8M | −$1.1M | −$2.4M | −$2.5M | −$3.1M | −$2.4M |
| EPS (diluted) | −$0.89 | −$36.02 | −$0.12 | −$11.91 | −$16.83 | −$12.96 | −$1.17 | −$6.30 | −$13.50 | −$0.78 | −$17.82 | −$14.94 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ARTL's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ARTL financial results
Artelo Biosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $12.9 million. Diluted earnings per share came to −$41.82.
See the ARTL stock overview for the latest quote and news, or the ARTL chart for price history and technical indicators.
ARTL income statement FAQ
Does Artelo Biosciences have revenue?
Artelo Biosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Artelo Biosciences profitable?
No. Artelo Biosciences reported a net loss of $12.9 million in fiscal 2025.
How much does Artelo Biosciences spend on research and development?
Artelo Biosciences spent $5.4 million on research and development in fiscal 2025.
What are Artelo Biosciences's earnings per share?
Artelo Biosciences earned $-41.82 per diluted share in fiscal 2025, compared with $-21.75 a year earlier.
When will Artelo Biosciences report its next earnings?
Artelo Biosciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Artelo Biosciences's fiscal year end?
Artelo Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.